@article{609e3830a6d24039bb6ab7e117538189,
title = "Guidelines of care for the management of cutaneous squamous cell carcinoma",
abstract = "Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease.",
keywords = "biopsy, curettage, metastasis, phototherapy, radiotherapy, squamous cell carcinoma, staging, surgery, surveillance, topical therapy",
author = "{Work Group} and {Invited Reviewers} and Murad Alam and April Armstrong and Christian Baum and Bordeaux, {Jeremy S.} and Marc Brown and Busam, {Klaus J.} and Eisen, {Daniel B.} and Vivek Iyengar and Clifford Lober and Margolis, {David J.} and Jane Messina and Alexander Miller and Stanley Miller and Eliot Mostow and Christen Mowad and Kishwer Nehal and Kristi Schmitt-Burr and Aleksandar Sekulic and Paul Storrs and Joyce Teng and Siegrid Yu and Conway Huang and Kevin Boyer and Begolka, {Wendy Smith} and Christopher Bichakjian and Kim, {John Y.S.} and Kozlow, {Jeffrey H.} and Bharat Mittal and Jeffrey Moyer and Thomas Olenecki and Phillip Rodgers",
note = "Funding Information: We thank Charniel McDaniels, MS, for technical assistance in the development of this manuscript. We also thank the AAD Board of Directors, the Council on Science and Research, the Clinical Guidelines Committee, and all commenting Academy members for their thoughtful and excellent feedback., The AAD strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies' Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The AAD conflict of interest policy summary may be viewed at, www.aad.org., Disclosure: The below information represents the authors' disclosed relationships with industry during guideline development. Relevant relationships requiring recusal for drafting of guideline recommendations and content by work group members were not noted for this guideline., April Armstrong, MD, MPH, served as an advisory board member for Abbvie, Amgen, Janssen-Ortho, Merck, Novartis, Pfizer and UCB, receiving honoraria; as a consultant for Celgene, Eli Lily, Jannsen-Ortho, and Modernizing Medicine, receiving honoraria; as a speaker for Abbvie, receiving honoraria; and as a principal investigator (PI) for Eli Lily, Janssen-Ortho, Novartis, and Regeneron, receiving grants/research funding. Jeremy S. Bordeaux, MD, MPH, served as an advisory board member for Lubax, receiving honoraria; as an employee of Massachusetts General Hospital, receiving a salary; and in another role with Journal Watch Dermatology, receiving honoraria. Marc Brown, MD, served as an advisory board member for DUSA Pharmaceuticals, receiving no compensation. David J. Margolis, MD, PhD, served as an advisory board member for Astellas, Celleration, and Kerecis, receiving fees; as a PI for Valeant, receiving grants/research funding; and as a Data Safety Monitoring Board member for DermaSciences, Macrocure, and Sanofi/Regeneron receiving fees. Stanley Miller, MD, served as an employee of UpToDate, Inc, receiving patent royalties and other compensation. Eliot Mostow, MD, MPH, served as a consultant for Elsevier, receiving a salary; as a speaker and PI for Healthpoint, receiving honoraria and grants/research funding; and as an advisory board member for Vivacare, receiving honoraria. Christen Mowad, MD, served on the Board of Directors for Elsevier, receiving honoraria; in other roles with UpToDate, Inc, receiving patient royalties and other compensation; and as a PI for Amgen, receiving fees. Dr. Mowad also had a relative serving as an employee of Takeda Pharmaceuticals receiving salary. Aleksander Sekulic, MD, PhD, served as an advisory board member for Roche and as a PI for Genentech, receiving fees. Conway Huang, MD, served as a consultant for Castle Biosciences, Inc, receiving honoraria. Murad Alam, M, served as a consultant for Amway, receiving honoraria, and as a PI for OptMed and 3M, receiving no personal compensation. Thomas Olenecki, DO, served as a PI for BMS, Exelixis, Genentech, Pfizer, and Tracon, receiving grants/research funding. Christopher Bichakjian, MD, Christian Baum, MD, Klaus J. Busam, MD, Daniel B. Eisen, MD, Vivek Iyengar, MD, Clifford Lober, MD, JD, Jane Messina, MD, Alexander Miller, MD, Kishwer Nehal, MD, Kristi Schmitt-Burr, Paul Storrs, MD, Joyce Teng, MD, PhD, Siegrid Yu, MD, John Y.S. Kim, MD, Jeffrey H. Kozlow, MD, MS, Bharat Mittal, MD, Jeffrey Moyer, MD, Phillip Rodgers, MD, Kevin Boyer, MPH, and Wendy Smith Begolka, MBS, have no relationships to disclose. Publisher Copyright: {\textcopyright} 2017 American Academy of Dermatology, Inc.",
year = "2018",
month = mar,
doi = "10.1016/j.jaad.2017.10.007",
language = "English (US)",
volume = "78",
pages = "560--578",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",
}